KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Gsk (GSK) Return on Capital Employed (2016 - 2026)

Gsk has reported Return on Capital Employed over the past 18 years, most recently at 9.49% for Q1 2026.

  • For Q1 2026, Return on Capital Employed rose 59.0% year-over-year to 9.49%; the TTM value through Mar 2026 reached 9.49%, up 59.0%, while the annual FY2025 figure was 9.84%, 116.0% down from the prior year.
  • Return on Capital Employed for Q1 2026 was 9.49% at Gsk, roughly flat from 9.46% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 26.36% in Q4 2023 and troughed at 5.23% in Q2 2022.
  • A 5-year average of 11.68% and a median of 9.63% in 2023 define the central range for Return on Capital Employed.
  • On a YoY basis, Return on Capital Employed climbed as much as 1429bps in 2022 and fell as far as -923bps in 2022.
  • Year by year, Return on Capital Employed stood at 22.24% in 2022, then rose by 19bps to 26.36% in 2023, then plummeted by -35bps to 17.15% in 2024, then crashed by -45bps to 9.46% in 2025, then rose by 0bps to 9.49% in 2026.
  • Business Quant data shows Return on Capital Employed for GSK at 9.49% in Q1 2026, 9.46% in Q4 2025, and 11.86% in Q3 2025.